Olema Oncology reports incentive grants pursuant to Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Sept. 4, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies for women's cancers, today announced that the Company has granted five new employees stock options to purchase an aggregate of 130,600 shares of the Company's common stock, effective September 3, 2024. These awards were approved by the Compensation Committee of Olema's Board of Directors and were granted under the Company's 2022 Incentive Plan with a grant date of September 3, 2024 as an incentive to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock options will vest over a four-year period, with 25 percent vesting on the first anniversary of the vesting date for the respective employee and the remainder vesting in 36 equal monthly installments over the following three years, provided that the employee is continuously employed by Olema on such vesting dates. The stock options have a 10-year term and an exercise price of $11.35 per share, which is the last reported sale price of the Company's common stock as reported by Nasdaq on September 3, 2024. The stock options are subject to the terms of Olema Pharmaceuticals, Inc.'s 2022 Incentive Plan.